Navigation Links
Hard To Treat Diseases (HTDS) Set To Acquire Cosmetics Company

CLEARWATER, FL, Jan. 7 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) the company is pleased to announce that it has identified a cosmetics company as a potential merger candidate. The cosmetics company also located in E Europe (Serbia) is engaged in online sales of the "Melem" product. Melem is a versatile, all-purpose skin and lip balm. It has a wide variety of skin and lip problems including eczema, psoriasis, chapped skin and lips, calluses, sunburns, insect bites and much more.

Andrea Rubio Zecevic, who currently acts as a head scientific advisor to HTDS said "Just to be clear, the Melem cosmetics company is not the core business of HTDS by any stretch of the imagination. It's a small self supporting cosmetics company and a nice add on for HTDS. The opportunities in this region due to the Balkan wars of the 1990s are enormous. There are various European Union reconstruction programs and enticements in place while the whole country is in the process of privatizing its entire infrastructure. Just to give our readers an example, HTDS will pay for the Melem cosmetics company a sum equivalent to a price of a USA based mid-sized car. This includes all the formulas, packaging the good will, the client base and whole back office. This is a fraction of the reproduction cost had we bought a similar company just 300-400 miles west in Switzerland or Austria or any other western European country. The company will complete the transaction on all cash basis. Currently this region of the world is celebrating the Orthodox Christmas. As soon as these holidays are behind them, we expect the final documents will be executed and the merger company name announced. In addition we are in contact with the Chief Scienist Dr. Sanja Pekovic who will shortly after the holidays commence furnishing us with regular updates on the progress her team has made with their work (see for details). Our aspirations for the merger with the Chinese based medical company engaged in the similar research as Slavica continues. The synergies are definitely present. Our representatives will be in Beijing next week and we should have some preliminary news to report on that front as well."

The company will provide further details as they become available.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

CONTACT: For scientific dialogue and any medical inquiry only please contact Andrea Rubio Zecevic via e-mail at For any corporate matters the readers should contact the company directly at

CONTACT: For scientific dialogue and any medical inquiry only please contact Andrea Rubio Zecevic via e-mail at For any corporate matters the readers should contact the company directly at

SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Warner Chilcott and Dong-A Sign U.S. License Agreement For Erectile Dysfunction Treatment
2. Kawasaki Disease Treated with Plasma-Derived Therapy
3. Unnecessary Spinal Surgery Will Waste Billions of Dollars in 2009 and Patients Will Continue to Suffer Unless the Primary Cause of Most Back Pain is Treated, Says Pain Specialist Norman Marcus, M.D.
4. Galderma Announces Availability of Epiduo(TM) Gel, the First and Only Combination Treatment with a Retinoid and Benzoyl Peroxide to Treat Acne
5. First RapidArc Radiotherapy Treatment in Italy Takes Place at Leading Milan Cancer Center
6. Dr. Mitchell L. Petusevsky, M.D., F.C.C.P. Meets Growing Demand for the Treatment of Sleep and Pulmonary Disorders
7. New Addiction Treatment Program Allows You to Attend Drug Rehabilitation and Still Keep Your Day Job
8. New appropriate use criteria guide treatment of patients with heart blockage
9. Cell death from cytomegalovirus may bring new life to treatment of retinal disease
10. Hard To Treat Diseases (HTDS) Completes E Europe Merger
11. Molecular imaging enables earlier, individualized treatment of thyroid cancer
Post Your Comments:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... of Australia,s successful biotechnology scientists, Dr ... company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm is ... the ASX. Noxopharm is a clinic-ready company with its ... clinical study later this year. ... facing cancer patients - the ability of cancers to become resistant ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
Breaking Medicine Technology: